Saturday, January 28, 2023
No Result
View All Result
  • বাংলা সংস্করণ
Shomporko
Advertisement
  • Home
  • News
    • Daily News
    • Feature
    • Sports
  • CANADA
    • Canada Daily
    • Community News
    • Canada Politics
    • Canada Economy
    • Canada Health
  • Global
  • Bangladesh
  • Interview
  • Article
    • Analytical
  • LITERATURE
    • Story
    • Poem
  • Opinion
    • Columnists
  • More
    • Food & Beverage
    • HISTORY
    • Kids Page
    • Travel
    • HOME DECOR
    • Video
    • Social Media
    • Festival
  • Home
  • News
    • Daily News
    • Feature
    • Sports
  • CANADA
    • Canada Daily
    • Community News
    • Canada Politics
    • Canada Economy
    • Canada Health
  • Global
  • Bangladesh
  • Interview
  • Article
    • Analytical
  • LITERATURE
    • Story
    • Poem
  • Opinion
    • Columnists
  • More
    • Food & Beverage
    • HISTORY
    • Kids Page
    • Travel
    • HOME DECOR
    • Video
    • Social Media
    • Festival
No Result
View All Result
Shomporko
No Result
View All Result
Home Health

Vancouver biotech firm could play a key role in developing COVID-19 vaccine

by Shomporko Online News Desk
July 4, 2020
in Health
0
Vancouver biotech firm could play a key role in developing COVID-19 vaccine
0
SHARES
34
VIEWS
Share on FacebookShare on Twitter

Shomporko Desk:- A Vancouver-based biotechnology company could play a key role in getting some of the first COVID-19 vaccines to market.

Acuitas Therapeutics is as of now joining forces with three groups, including one backed by drug giant Pfizer and one out of Imperial College London, who have entered Phase I/II clinical vaccine trials.

BioNTech, which has partnered with Pfizer, started its trials back in April, while CureVac and Imperial College started trials a month ago.

Acuitas president Tom Madden says researchers are planning to utilize Messenger RNA to make a resistant reaction that protects against COVID-19.

Acuitas’ role in the vaccines is the creation of a delivery method to get that material into the body.

“We provide microscopic carriers, lipid nanoparticles, that protect the MRNA after its injected and carry it into cells so that it can work,” he said.

“At the moment, lipid nanoparticles are by far the best delivery technology that’s available.”

The technology was actually developed in the 1990s to deliver traditional medications, but Madden said his company has spent the last decade researching how to use them with nucleic acid therapeutics — new classes of drugs based on biological molecules.

The proposed MRNA vaccines still need wider human testing, and to clear regulatory hurdles before they could be generally distributed.

But Madden said his company is already working with its partners about how to scale up lipid nanoparticle production should they get the green light.

“What are some of the pitfalls we have to overcome? What are some of the challenges we have to overcome so we could make literally hundreds of millions of doses of the vaccine if it becomes approved for use in the general population?” he said.

Last week, U.S. National Institute of Allergy and Infectious Diseases director Dr. Anthony Fauci said he remains cautiously optimistic there will be a COVID-19 vaccine by the end of the year or early 2021.

However, other researchers have warned that getting a product to market within two years would be a “best-case scenario.”

Photo credit: Getty Images

News source: Global News

Previous Post

U.K. PM says no U.S. approach to quiz Andrew

Next Post

Canada and the U.S. excluded from British travel list

Shomporko Online News Desk

Related Posts

Nearly 30 per cent of kids ages 5-11 in Toronto have received 1st dose of COVID-19 vaccine
Canada Daily

Nearly 30 per cent of kids ages 5-11 in Toronto have received 1st dose of COVID-19 vaccine

December 10, 2021
COVID-19: Where the major parties stand on vaccine passports
Canada Health

COVID-19: Where the major parties stand on vaccine passports

September 3, 2021
Ontario reports largest increase in COVID-19 cases since early June, 1 additional death
Dailynews

Ontario reports largest increase in COVID-19 cases since early June, 1 additional death

August 21, 2021
Faculty groups at McGill University call for COVID-19 vaccine mandate
Canada Daily

Faculty groups at McGill University call for COVID-19 vaccine mandate

August 20, 2021
Facebook says it’s ‘not the reason’ U.S. is failing to meet COVID-19 vaccine goals
Global

Facebook says it’s ‘not the reason’ U.S. is failing to meet COVID-19 vaccine goals

July 18, 2021
WHO still struggling to manage the pandemic response
Global

WHO still struggling to manage the pandemic response

March 12, 2021
Next Post
Canada and the U.S. excluded from British travel list

Canada and the U.S. excluded from British travel list

Logo

Disclaimer:

The editorial team is not responsible for the content of the writing.

Publisher and Editor
Sonia Hoque

General Manager

Rewrite-Man

Reporter

Graphics
Mozammel Sarkar

Address:

Shomporko Magazine

59 Byng ave
Scarborough,
Ontario
M1L3N8

Phone :647-686-5432

 

Email: 
shomporko.magazine@gmail.com
2537765 Ontario Ltd

© 2020 Shomporko – Magazine Develop by RMITtech

No Result
View All Result
  • Home
  • NEWS
    • Daily News
    • Feature
    • Global
    • Politics
    • Sports
  • CANADA
    • Canada Daily
    • Community News
    • Canada Politics
    • Canada Economy
    • Canada Immigration
    • Canada Education
    • Canada Health
    • Canada Opinion
  • GLOBAL
  • INTERVIEW
  • ARTICLE
    • Analytical
  • LITERATURE
    • Story
    • Poem
  • OPINION
    • Opinion
    • Columnists
    • Legal Advice
  • ARTS
    • Home Decor
    • Sports
  • LIVING
    • Health
    • Food
    • Travel
    • HISTORY
    • Kids Page
  • MORE
    • Video
    • Social Media
    • Festival
  • বাংলা সংস্করণ

© 2019 Shomporko - Magazine Develop by RMITtech.

Translate »